ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Published on by Top Pharmaceutical

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Dr. ATSUSHI HOSUI, Osaka Rosai Hospital, Japan

Dr. Atsushi Hosui, a distinguished hepatologist, earned his M.D. from Osaka University in 1994 🎓. With Japanese Medical License #363021, he holds multiple board certifications in internal medicine, gastroenterology, and hepatology 🏥. Currently serving as Director of Hepatology at Osaka Rosai Hospital, he has led and contributed to numerous clinical trials on NASH, MASH, PBC, and liver cancer 🧬. A member of Japan’s leading medical societies, he is also GCP-trained (2015) 📋. Renowned for his impactful research and over 30 scientific publications, Dr. Hosui is a trailblazer in liver disease therapeutics and pharmaceutical excellence.

Publication Profile 

Scopus

Education

Dr. Atsushi Hosui embarked on his medical journey at the prestigious Osaka University, Japan 🗾, where he earned his Doctor of Medicine (M.D.) degree in March 1994 🎓. Renowned for its excellence in medical education and research, Osaka University provided him with a solid foundation in clinical medicine and scientific inquiry 🧪. His education laid the groundwork for a remarkable career in gastroenterology and hepatology 🏥. Driven by a passion for improving liver health, Dr. Hosui has since become a respected physician, researcher, and clinical investigator, dedicated to advancing pharmaceutical science and patient care globally.

Awards

Dr. Atsushi Hosui holds a prestigious Japanese Medical License (#363021) 🇯🇵, validating his long-standing commitment to clinical excellence. He is a board-certified member and specialist of the Japanese Society of Internal Medicine 🧬, where he also serves as an advising doctor 👨‍⚕️. His specialization extends to gastroenterology and hepatology, holding certified status from the Japanese Society of Gastroenterology 🏥, the Japan Society of Hepatology 🏆, and the Japan Gastroenterological Endoscopy Society 🔬. These recognitions underscore his expertise in digestive health and liver diseases, reflecting a distinguished career devoted to patient care and research innovation.

Experience

Dr. Atsushi Hosui has led and contributed to numerous groundbreaking clinical research projects in hepatology and internal medicine 🧬. As an investigator or sub-investigator, he played key roles in studies on NASH (2021–2022) and MASH (2024–2025) 🩺. His focus on hypozincemia (2015), hepatocellular carcinoma (2012–2016), portal vein thrombosis (2015–2016), and PBC (2025–) highlights his expertise in liver-related conditions 🧠. He also contributed significantly to studies on thrombocytopenia and chronic hepatitis C (2013) 🧫. Dr. Hosui’s research dedication reflects his mission to improve liver health and advance pharmaceutical excellence globally.

Research Focus

Dr. Atsushi Hosui’s research is centered around hepatology and gastroenterology, with a strong emphasis on hepatocellular carcinoma (HCC) 🧫, chronic liver diseases 🏥, and vascular complications like gastric varices and Budd-Chiari syndrome 🫀. His clinical investigations span topics such as portal hypertension, black esophagus, hyperglycemic complications, and the long-term risks of hepatitis B treatments 🦠. His innovative approaches combine locoregional therapies, embolization techniques, and pharmacologic interventions to enhance liver cancer outcomes 🎯. Dr. Hosui’s work bridges diagnostic precision with therapeutic advancements in liver-related pathologies, reinforcing his role as a leader in hepatic disease management.

Publication Top Notes

  • Management of Gastric Varices with Portopulmonary Venous Anastomosis: A Combined Approach Using Percutaneous Transhepatic Coil Embolization and Balloon-Occluded Retrograde Transvenous Obliteration
  • Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
  • Black Esophagus in Hyperosmolar Hyperglycemic Syndrome
  • The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs
  • Solitary Cardiac Metastasis of Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Associated with Secondary Budd-Chiari Syndrome

juan iovanna | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Surya Nandan Meena | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Surya Nandan Meena | Drug Discovery and Development | Best Researcher Award

Dr. Surya Nandan Meena, Savitribai Phule Pune University, India

Dr. Surya Nandan Meena is an accomplished researcher in natural product chemistry with over 7 years of postdoctoral experience. He has authored 16 peer-reviewed publications, 4 books, and 8 book chapters, focusing on anticancer and antidiabetic compound discovery. 🧬 His expertise spans LC-MS/MS, molecular docking, and mammalian cell assays. 🎓 A recipient of prestigious fellowships like the Dr. D.S. Kothari and SERB-DST, he has led international projects, mentored students, and contributed to multidisciplinary science globally. 🌱 Passionate about drug discovery and marine biotechnology, Dr. Meena actively serves on editorial boards and scientific societies worldwide.

Publication Profile

Google Scholar

Education

Dr. Surya Nandan Meena is a dedicated scholar with a robust academic background in biotechnology and agriculture. He earned his Ph.D. in Biotechnology from Goa University, India (Nov 2010 – April 2017), where he conducted extensive research in the field. Prior to that, he completed his M.Sc. in Plant Biotechnology from UAS Dharwad, India (July 2006 – April 2009), further refining his expertise in plant sciences 🌿. His academic journey began with a B.Sc. (Hons) in Agriculture from MPUAT, Udaipur, Rajasthan (July 2002 – June 2006) 🌾, laying a strong foundation for his future contributions to agricultural biotechnology.

Awards

Dr. Surya Nandan Meena has been honored with numerous prestigious awards and research fellowships throughout his academic journey. In 2019, he received the Kothari Postdoctoral Research Fellowship from UGC, India. He earned the Best Research Paper Appreciation Award from Anchrome Pvt. Ltd. in 2018 📜. In 2017, he was awarded the National Postdoctoral Fellowship by SERB-DST, India. His dedication was also recognized with the Senior Research Fellowship from DBT in 2013 and the Best Poster Presentation Award in 2012 🧪. Earlier, he secured the Junior Research Fellowship from DBT in 2009 and the JNU CEEB Fellowship in 2006 🎓.

Experience

Dr. Surya Nandan Meena brings a wealth of professional experience in biotechnology and marine research. Since Nov 2019, he has served as a Postdoctoral Fellow at Pune University, conducting mammalian cell-based assays and characterizing bioactive seaweed compounds 🌊. Earlier, at the National Institute of Oceanography (2017–2019), he surveyed 35+ seaweed species and contributed to multiple publications 📚. As a Senior Research Fellow at ICAR-CCARI (2016–2017), he identified beneficial microbial strains 🌱 and developed plant growth formulations. His roles also included mentoring students, publishing in high-impact journals, and leading interdisciplinary research, reflecting his dedication to scientific innovation and collaboration 👨‍🔬.

Research Focus

Dr. Surya Nandan Meena’s research centers on natural product chemistry, sustainable bioresource utilization, and drug discovery. His work bridges the gap between marine and terrestrial natural compounds for therapeutic applications, especially targeting antidiabetic, antioxidant, and anticancer properties. With notable contributions in biocatalysis, phytochemistry, and biosynthetic pathways, Dr. Meena emphasizes green, solvent-free synthesis and eco-friendly resource management. He actively explores seaweed farming, plant-based compounds, and essential oils as potent sources for novel bioactives. His multidisciplinary approach contributes significantly to natural compound-based drug development and sustainable healthcare innovation.

Publication Top Notes

Natural resources conservation and advances for sustainability

Graphite catalyzed solvent free synthesis of dihydropyrimidin-2 (1H)-ones/thiones and their antidiabetic activity

Seaweed Farming: A Perspective of Sustainable Agriculture and Socio-economic Development

Advances in Biological Science Research: A Practical Approach

Biosynthesis of vanillic acid by Ochrobactrum anthropi and its applications

α-Glucosidase inhibition activity and in silico study of 2-(benzo [d][1, 3] dioxol-5-yl)-4H-chromen-4-one, a synthetic derivative of flavone

Quick Identification of Piperidine Alkaloid from Roots of Grewia nervosa and Their Glucosidase Inhibitory Activity

Antioxidant and antiglycemic properties of macroalgae, an underutilized blue economy bioresource in India

Evaluation of silver-doped indium oxide nanoparticles as in vitro α-amylase and α-glucosidase inhibitors

New horizons in natural compound research

Biodegradation of seafood waste by seaweed-associated bacteria and application of seafood waste for ethanol production

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Hui Huang | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Hui Huang | Precision Medicine | Best Researcher Award

Prof. Dr. Hui Huang, The Eighth Affiliated Hospital of Sun Yat-Sen University, China

Prof. Hui Huang is Vice President of The Eighth Affiliated Hospital of Sun Yat-sen University and a renowned expert in vascular calcification and chronic disease prevention. 📚 He has authored 100+ high-impact papers in journals like Circulation and J Clin Invest, earning honors like ESI Highly Cited and Top 100 High-Value Papers. 🏆 A recipient of China’s Excellent Young Scientists Fund, he directs multiple prestigious laboratories and holds several international patents. 🔬 His research explores metabolic and immune mechanisms in chronic kidney disease and vascular aging.

Publication Profile

Scopus

Education

Prof. Dr. Hui Huang has authored over 100 peer-reviewed papers in prestigious journals such as Circulation (2022, 2023), J Clin Invest. (2021, 2022, 2025), Hypertension (2018, 2021, 2022), STTT (2022–2024), Kidney Int. (2024), and Cardiovasc Res. (2023) 📚. His impactful work has earned distinctions like ESI Highly Cited Papers, Top 100 High-Value Papers, and journal Cover Stories 🏅. A recipient of China’s National Science Fund for Excellent Young Scholars 🎓, he also led the development of the Expert Consensus on Vascular Calcification, offering vital clinical guidance for practitioners in the field of cardiovascular and renal medicine ❤️🩺.

Experience

Prof. Dr. Hui Huang has led more than 13 major research projects, predominantly funded by the National Natural Science Foundation of China (NSFC) 🔬🇨🇳. His groundbreaking work focuses on unraveling the innovative mechanisms behind arterial calcification, chronic kidney disease, and inflammation 🧠🫀. These projects are long-term, high-budget, and scientifically robust, highlighting their critical importance on both national and global stages 🌍💰. Through his pioneering research, Prof. Huang is driving transformative advancements in cardiovascular and renal health, contributing significantly to medical science and improving patient outcomes 🚀🩺.

Research Focus

Prof. Dr. Hui Huang is a leading researcher in biomedical sciences, with a strong focus on cardiovascular disease, immunology, toxicology, and metabolic disorders. Her work spans areas such as inflammation in the central nervous system, myocardial infarction, diabetes-related metabolomics, and environmental health risks like metal toxicity. 🌡️🧠🫀 She also explores digital therapeutics and sex-based differences in disease outcomes, making her contributions highly interdisciplinary. 📊💻 Her research integrates clinical, molecular, and environmental insights to develop novel strategies for disease prevention and treatment. A strong advocate for translational medicine, Prof. Huang bridges lab science with real-world health challenges.

Publication Top Notes

The Innate Immune Sensor Zbp1 Mediates Central Nervous System Inflammation Induced by Angiostrongylus Cantonensis by Promoting Macrophage Inflammatory Phenotypes

Targeted LC-MS/MS method of oxylipin profiling reveals differentially expressed serum metabolites in type 2 diabetes mice with panaxynol

Ellagic acid-enhanced biocompatibility and bioactivity in multilayer core-shell gold nanoparticles for ameliorating myocardial infarction injury

Sex difference in human diseases: mechanistic insights and clinical implications

Effect of plateletcrit and methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on folic acid efficacy in stroke prevention

Digital therapeutics in hypertension: How to make sustainable lifestyle changes

Associations of essential metals with the risk of aortic arch calcification: a cross-sectional study in a mid-aged and older population of Shenzhen, China

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. KYU SHIK MUN, Cedars-Sinai Medical Center, United States

Assist. Prof. Dr. Kyu Shik Mun is a distinguished researcher in cystic fibrosis (CF) and biomedical engineering 🧬. As a Principal Investigator and Co-Director, he has led groundbreaking projects on CF-related diabetes, organ-on-a-chip models, and personalized CF therapy 🏥. His work, funded by organizations like the Cystic Fibrosis Foundation and Vertex Pharmaceuticals, has yielded significant patents and high-impact publications 📑. With 733 citations, an h-index of 10, and an i10-index of 10, Dr. Mun continues to drive innovations in CF research, bridging biomedical science and translational medicine 🔬.

Publication Profile

Google Scholar

Professional Background

Assist. Prof. Dr. Kyu Shik Mun earned his Ph.D. in the Materials Science and Engineering Program at the University of Cincinnati 🎓. In 2016, he joined the Cystic Fibrosis Research Center at Cincinnati Children’s Hospital, where he pioneered a microfluidic-based organ-on-chip program from scratch 🏥🧬. His groundbreaking research focused on studying cystic fibrosis and related disorders. In 2021, he was promoted to Assistant Professor at Cedars-Sinai 🏆, where he continues to advance in vitro cell culture models using organ-on-chip technology and 3D bioprinting 🖨️🔬, contributing to innovative solutions in biomedical research and personalized medicine.

Awards

Assist. Prof. Dr. Kyu Shik Mun has received numerous prestigious honors and awards throughout his academic and professional journey 🎖️. He was awarded multiple Outstanding Grade Scholarships at Gangneung National University 🏅 (2000–2009) and recognized for excellence with department and presidential awards 🏆. His achievements include a scholarship from the Korean Broadcasting System 📺 and the Korea Research Foundation 🌏. During his Ph.D. at the University of Cincinnati, he earned a University Graduate Scholarship 🎓 (2010–2014). His research has been recognized by the American Gastroenterological Association and the Cystic Fibrosis Foundation 🧬, receiving multiple Best Abstract and Early Career Investigator awards (2017–2024) 🥇.

Experience 

Assist. Prof. Dr. Kyu Shik Mun has been actively involved in non-clinical teaching, contributing to journal clubs and lab mentoring 📚🎤. He has delivered key presentations on organ-on-a-chip technology 🧬, including talks at Cincinnati Children’s Hospital (2020) and Cedars-Sinai (2021) 🏥. His mentorship spans postdoctoral fellows, research associates, and Ph.D. students, guiding projects in 3D bioprinting 🖨️ and patient-derived lung-on-a-chip models 🌬️. Since 2016, he has mentored 15 summer and rotation students—including high school, college, Ph.D., and MD candidates—on fabricating organ-on-a-chips and culturing cells, fostering the next generation of biomedical researchers 🔬.

Research Focus

Assist. Prof. Dr. Kyu Shik Mun’s research primarily focuses on nanotechnology 🧪, biosensors 🧫, and biomedical engineering 🏥. His work spans optical interferometric biosensors for label-free detection, organ-on-a-chip models for diseases like cystic fibrosis 🫁, and TiO₂ nanotube arrays for applications in solar cells ☀️ and photocatalysis. He also explores drug discovery 💊 by targeting molecular pathways in cystic fibrosis and related disorders. His interdisciplinary research integrates materials science 🏗️, biophysics ⚛️, and microfluidics 🔬 to develop innovative medical technologies, aiming to advance precision medicine 🎯 and renewable energy solutions 🌱.

Publication Top Notes

A Stable, Label-free Optical Interferometric Biosensor Based on TiO2 Nanotube Arrays

Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders

Guided construction of single cell reference for human and mouse lung

Targeting the pregnane X receptor using microbial metabolite mimicry

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations

Surface passivation of highly ordered TiO2 nanotube arrays and application to dye-sensitized solar cells using the concept of isoelectric point

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue ΔF508-CFTR

Guanylate cyclase 2C agonism corrects CFTR mutants

Cystic Fibrosis Human Organs-on-a-Chip

Nibras Mohammed Sahi | Drug Delivery Systems | Women Researcher Award

Published on by Top Pharmaceutical

Nibras Mohammed Sahi | Drug Delivery Systems | Women Researcher Award

Assist. Prof. Dr. Nibras Mohammed Sahi, Ministry of Higher Education and Scientific Research, University of Babylon, Iraq

Dr. Nebras Mohammed Sahi 🦋, an Assistant Professor at the University of Babylon, specializes in entomology and plant extracts 🌿. Her research explores insect-derived products and medicinal plant applications in anticancer and antibacterial treatments 🧪. She has contributed to high-impact journals 📄 indexed in SCI and Scopus. Dr. Sahi prepared the propolis and Alhagi maurorum extract used in her latest research. Her work advances medicine, agriculture, and sustainability 🌍. With a citation index of 3, she actively collaborates on innovative biological studies. 💡🔬

Publication Profile

orcid

Professional Background

Dr. Nibras Mohammed Sahi 🦋, an Assistant Professor, specializes in entomology and plant extracts, focusing on the study of insects and their beneficial products. Her research explores the diverse applications of insect-derived compounds in medicine 💊, agriculture 🌱, and sustainability 🌍. Through collaborations with universities and research institutions, she investigates innovative ways to harness the potential of insects for ecological and economic benefits. Driven by a passion for scientific discovery 🔬, Dr. Sahi’s work contributes to advancements in bio-based solutions, aiming to enhance environmental conservation and agricultural productivity while promoting sustainable development.

Ongoing Research

Dr. Nibras Mohammed Sahi 🦋 is actively engaged in research on insect-derived products and plant extracts, with a particular focus on propolis 🐝 and Alhagi maurorum 🌿 for cancer 🧬 and antibacterial 🦠 applications. Her studies explore the therapeutic potential of these natural compounds, aiming to develop innovative solutions in medicine 💊 and biotechnology. While her work aligns with prestigious award categories, highlighting specific project funding 💰, collaborations 🤝, or research grants would further strengthen her academic profile. Through her dedication to scientific discovery 🔬, Dr. Sahi contributes to advancements in natural product research and sustainable healthcare solutions.

Professional Memberships

Dr. Nibras Mohammed Sahi 🦋 has not listed any editorial appointments, active collaborations, or professional memberships. However, participation in scientific societies 🏛️, international conferences 🎤, or editorial boards 📑 would significantly enhance her academic profile. Engaging in peer-reviewed journals 📚, contributing to scientific committees 🏅, or collaborating on global research initiatives 🌍 would further establish her influence in the field of entomology and natural product research. Highlighting such professional engagements would strengthen her candidacy, showcasing her dedication to advancing scientific knowledge 🔬 and fostering collaborations that drive innovation in medicine 💊, agriculture 🌱, and sustainability 🌿.

Research Focus

Assist. Prof. Dr. Nibras Mohammed Sahi’s research primarily focuses on microbiology 🦠, antibiotic resistance 💊, and bioactive compounds 🌱. His studies encompass pathogenic bacteria identification 🧫, antimicrobial activity testing 🧪, and molecular genetics 🧬 related to infectious diseases. He has extensively investigated natural plant extracts 🌿 and fungal metabolites 🍄 for their antibacterial and antifungal properties, along with genetic factors in diseases 🧑‍⚕️ like hepatitis B and colorectal cancer. His work also extends to insecticidal bioactive compounds 🪲 and their effects. His research contributes significantly to public health 🏥, pharmacology 💉, and molecular diagnostics 🔬.

Publication Top Notes

Molecular & Antibiotic Sensitivity Pattern Study of Acute Otitis Media, Tonsillitis & Periodontitis among Different Ages of Patients of Al-Hashmia General Hospital, Primary Care Centers & Private Clinic in Babylon Province

Analysis of Methanolic extract of Secondary Metabolites Released by Candida glabratus using GC-MS and Evaluation of Its Antimicrobial Activity

Detection of Bioactive Compounds of Raphanus sativus Using GC-MS and FT-IR Technical Analysis and Determination of its Anti-Bacterial and Anti-Fungal Activity.

Isolation and Identification of Some Pathogenic Bacteria from Otitis Media in Babylon Governorate

Antimicrobial Effect of the Crude Phenolic, Alkaloid and Terpenoid Compounds Extracts of Myrtus Communis L. against Human Gram-Negative Pathogenic Bacteria

Antimicrobial Effect of the Crude Phenolic, Alkaloid and Terpenoid Compounds Extracts of Myrtus Communis L. against Human Gram-Negative Pathogenic Bacteria

Chuan Fan | Nanomedicine | Best Researcher Award

Published on by Top Pharmaceutical

Chuan Fan | Nanomedicine | Best Researcher Award

Dr Chuan Fan,Linyi University,China

Dr. Chuan Fan 🎓🔬 is a lecturer at Linyi University’s School of Chemistry and Chemical Engineering, specializing in multifunctional hydrogel dressing systems and acoustic-driven biomarker analysis. He earned his degree from the University of Science and Technology Beijing under Prof. Xueji Zhang. With 30+ SCI- and Scopus-indexed publications and a ResearchGate citation index of 984, his research contributes to pharmacology and drug delivery. However, he is in the early stages of securing patents, grants, and industry collaborations. His work holds promise for advanced therapeutic applications, making him a strong contender for early-career research awards. 🏆📚

Publication Profile

Scopus

Academic and Professional Background

Dr. Chuan Fan 🎓 pursued his studies at the University of Science and Technology Beijing under the esteemed mentorship of Professor Xueji Zhang. Since August 2023, he has been serving as a lecturer at Linyi University’s School of Chemistry and Chemical Engineering 🏫. His research primarily focuses on multifunctional hydrogel dressing systems and acoustic-driven enrichment analysis of trace biomarkers 🧪. Through his dedication and innovation, Dr. Fan has made significant progress in his field, contributing to multiple high-quality publications in indexed journals 📚. His work continues to advance scientific knowledge and practical applications in chemical and biomedical research. 🚀

Research and Innovations

Dr. Chuan Fan has made notable contributions to his field, authoring over 30 SCI- and Scopus-indexed articles 📄, reflecting his dedication to research. His citation index on ResearchGate stands at 984 🔍, indicating a moderate academic impact. However, his research engagement appears to be in its early stages, with no completed projects and only two ongoing ones 🧪. Despite his publication record, he has yet to secure patents, editorial appointments, industry collaborations, consultancy projects, or book publications 📚. While his work is promising, further achievements in these areas could enhance his influence in the scientific community. 🌟

Contributions and Impact

Dr. Chuan Fan is dedicated to advancing pharmacology and drug delivery systems, with a focus on enhancing targeted therapies and improving patient outcomes 💊🔬. His research explores innovative methods to optimize drug efficacy and minimize side effects, contributing to the evolving landscape of precision medicine. While he asserts that his work has gained significant recognition, concrete evidence such as prestigious awards, keynote invitations, or high-impact citations remains unspecified 🏆📖. Despite this, his contributions reflect a commitment to revolutionizing drug delivery, potentially shaping future advancements in personalized treatment strategies for various medical conditions 🚀🧬.

Professional Engagements

Dr. Chuan Fan currently does not hold any professional memberships, editorial roles, or collaborative positions, which are key indicators of a researcher’s influence in the academic community 📚. Actively participating in international conferences 🌍, joining professional societies 🏛️, and engaging in research networks 🔬 would significantly enhance his professional standing. Such involvement fosters knowledge exchange, strengthens collaborations, and increases visibility within the scientific community. By contributing to peer-reviewed journals ✍️, networking with experts 🤝, and taking on leadership roles, Dr. Fan can expand his impact and establish himself as a recognized authority in his field of expertise.

Research Focus

Dr. Chuan Fan’s research focuses on biomedical materials 🧪, nanotechnology 🧫, and wound healing 🩹, particularly in developing visible light-activated Ti-MOF (titanium-metal-organic frameworks) hydrogel composites for chronic diabetic wound healing 🦶. His work integrates photocatalysis 🌞, drug delivery 💊, and biocompatible hydrogels to enhance tissue regeneration and antimicrobial effects. By loading metformin into these advanced biomaterials, Dr. Fan aims to promote faster and more effective healing of diabetic wounds, addressing a critical medical challenge. His research sits at the intersection of materials science 🏗️, biomedical engineering ⚙️, and regenerative medicine 🧬.

Publication Top Notes

Visible light-activated Ti-MOF loaded metformin-hydrogel composite dressing for accelerated chronic diabetic wound healing